secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0000784199-25-000069
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q1 revenue $99M (+2% GAAP), net loss $0.5M; raises FY 2025 guidance
----------------------------------------------------------------------------

- Revenue $99.0M, up 2% GAAP (4% constant currency); net loss $(0.5)M vs net income $7.5M in Q1 2024.
- Non-GAAP net income $2.5M ($0.06 diluted); adjusted EBITDA $17.5M (+1% YoY).
- Product growth: stent grafts +14%, On-X +10%, BioGlue +7%; preservation services -23% from cyber backlog.
- FY 2025 guidance raised: revenue $423-435M (11-14% constant currency growth); adj. EBITDA $84-91M.
- Positive 30-day NEXUS data (63% MAE reduction); PMA submitted for AMDS Hybrid Prosthesis to FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419925000069/0000784199-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419925000069/aort-20250505.htm
  HTML page:      https://secwatch.observer/filing/0000784199-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer